journal
MENU ▼
Read by QxMD icon Read
search

Seminars in Thrombosis and Hemostasis

journal
https://www.readbyqxmd.com/read/28052306/laboratory-monitoring-of-parenteral-direct-thrombin-inhibitors
#1
Elizabeth M Van Cott, A Joshua Roberts, William E Dager
Argatroban and bivalirudin are parenteral direct inhibitors of the activity of thrombin, but, unlike heparin, can inhibit both soluble as well as clot-bound thrombin. These agents do not require antithrombin as a cofactor for activity. The parenteral direct thrombin inhibitors (DTIs) can be used in a variety of settings, including heparin-induced thrombocytopenia (HIT) or an allergy to heparin, and patients requiring anticoagulation for an invasive cardiovascular intervention. Both agents have a relatively short half-life in patients without organ system failure and are typically administered by continuous infusion...
January 4, 2017: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/28052305/plasmin-ogen-at-the-nexus-of-fibrinolysis-inflammation-and-complement
#2
Jonathan H Foley
The diverse mechanisms by which the plasmin(ogen) system is involved in human physiology and pathology are constantly being delineated. For many years, the plasmin(ogen) system was chiefly known as the system responsible for vascular fibrinolysis. Although this is an important function of the plasmin(ogen) system, we now recognize that plasmin(ogen) is critically important as a mediator of inflammation and the innate immune system, which impacts upon a diverse set of mechanisms underlying the pathologies of many diseases...
January 4, 2017: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/28008575/response-to-innovation-in-hemophilia-therapies-and-miles-to-go-before-we-sleep
#3
Pier Mannuccio Mannucci, Massimo Franchini
No abstract text is available yet for this article.
December 22, 2016: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/27992938/bortezomib-potential-key-role-in-the-treatment-of-multiple-myeloma-related-acquired-hemophilia-a
#4
Gil de Paiva Brás, Ricardo Jorge Sancio Moreira Pinto, Maria Manuela Marques Cardoso Carvalho, Susana Patrícia Beleza Nobre Fernandes, Joaquim José Aguiar Andrade, José Eduardo Torres Eckenroth Guimarães
No abstract text is available yet for this article.
December 19, 2016: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/27978591/phenotypic-parameters-in-genotypically-selected-type-2b-von-willebrand-disease-patients-a-large-single-center-experience-including-a-new-novel-mutation
#5
Adriana Ines Woods, Ana Catalina Kempfer, Juvenal Paiva, Analia Sanchez-Luceros, Emilse Bermejo, Roberto Chuit, Maria Fabiana Alberto, Alicia Noemi Blanco, Maria Angela Lazzari
von Willebrand disease type 2B (VWD2B) expresses gain-of-function mutations that enhance binding of an individual's von Willebrand factor (VWF) to its platelet ligand, glycoprotein Ib (GPIb), and which are usually identified by increased ristocetin-induced platelet aggregation (RIPA). We describe here the phenotypic profile of 38 genotypically selected VWD2B-affected family members (AFMs) belonging to 19 unrelated families. Major bleeding was observed in 68.4% of AFMs (previous to their diagnosis and registered by lifetime interviews), with a total of 46 episodes (1...
December 15, 2016: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/27978590/laboratory-testing-for-von-willebrand-disease-the-past-present-and-future-state-of-play-for-von-willebrand-factor-assays-that-measure-platelet-binding-activity-with-or-without-ristocetin
#6
Sarah Just
von Willebrand disease (VWD) was first described nearly a century ago in 1924 by Erik Adolf von Willebrand. Diagnostic testing at the time was very limited and it was not until the mid to late 1900s that more tests became available to assist with the diagnosis and classification of VWD. Two of these tests are based on ristocetin, one being ristocetin-induced platelet aggregation (RIPA) and the other the von Willebrand factor (VWF) ristocetin cofactor assay (VWF:RCo). The VWF:RCo assay provides functional assessment of in vitro VWF binding to the platelet glycoprotein (Gp) complex, GPIb-IX-V...
December 15, 2016: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/27978589/gene-variations-in-the-protein-c-and-fibrinolytic-pathway-relevance-for-severity-and-outcome-in-pediatric-sepsis
#7
Navin P Boeddha, Marieke Emonts, Marjon H Cnossen, Moniek P de Maat, Frank W Leebeek, Gertjan J Driessen, Jan A Hazelzet
The host response to infection involves complex interplays between inflammation, coagulation, and fibrinolysis. Deregulation of hemostasis and fibrinolysis are major causes of critical illness and important determinants of outcome in severe sepsis. The hemostatic responses to infection vary widely between individuals, and are in part explained by polymorphisms in genes responsible for the protein C and fibrinolytic pathway. This review gives an overview of genetic polymorphisms in the protein C and fibrinolytic pathway associated with susceptibility and severity of pediatric sepsis...
December 15, 2016: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/27978588/innovation-in-hemophilia-therapies-and-miles-to-go-before-we-sleep
#8
Albert Farrugia
No abstract text is available yet for this article.
December 15, 2016: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/27923263/microparticles-and-fibrinolysis
#9
Loris Vallier, Sylvie Cointe, Romaric Lacroix, Amandine Bonifay, Coralie Judicone, Françoise Dignat-George, Hau C Kwaan
Microparticles (MPs) are submicronic vesicles which are formed by budding of the cellular membrane of virtually any cell type in response to cell activation or apoptosis. Both circulating MPs and MPs generated within tissues harbor molecules with a large repertoire of biological activities and transfer material to target cells. Depending on their cellular origin, the stimuli triggering their formation, or their localization, they may participate in the maintenance of organ or vascular homeostasis as well as inducing dysfunction...
December 6, 2016: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/27907937/tranexamic-acid-for-trauma-resuscitation-in-the-united-states-of-america
#10
Mark Walsh, Scott Thomas, Ernest Moore, Hunter Moore, Andres Piscoya, Daniel Hake, Michael Son, Tim Pohlman, Julie Wegner, John Bryant, Alberto Grassetto, Patrick Davis, Nathan Nielsen, Anton Crepinsek, Jacob T Shreve, Francis Castellino
The utilization of tranexamic acid (TXA) for the management of bleeding trauma patients has been a subject of much debate on both sides of the Atlantic and in Australia. As a result of the large randomized controlled study called the Clinical Randomization of an Antifibrinolytic in Severe Hemorrhage (CRASH-2), there was an initial enthusiasm for the use of TXA to treat bleeding patients. However, the adoption of TXA in the United States was delayed by concerns of "knowledge and evidence gaps" of the CRASH-2 study and because of a lack of mechanistic rationale that would explain the survival benefit noted in the study...
December 1, 2016: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/27825182/practical-aspects-of-monitoring-of-antiplatelet-therapy
#11
Ljubica Jovanovic, Nebojsa Antonijevic, Tina Novakovic, Nebojsa Savic, Branka Terzic, Ivana Zivkovic, Nebojsa Radovanovic, Milika Asanin
Despite the application of new antiplatelet drugs (prasugrel and ticagrelor), dual antiplatelet therapy with clopidogrel and aspirin remains the standard for patients with acute coronary syndrome undergoing percutaneous coronary intervention, especially in countries of low socioeconomic status. Regardless of the proven benefits, numerous studies have shown that certain groups of patients who receive standard doses of clopidogrel and aspirin do not respond adequately, and many of them also exhibit adverse cardiovascular events...
November 8, 2016: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/27825181/blood-group-o-protects-against-inhibitor-development-in-severe-hemophilia-a-patients
#12
Massimo Franchini, Antonio Coppola, Carlo Mengoli, Gianna Franca Rivolta, Federica Riccardi, Giovanni Di Minno, Annarita Tagliaferri
Increasing evidence supports the link between ABO(H) blood group determinants and hemostasis. In particular, the ABO-related different glycosylation patterns of von Willebrand factor strongly influence its clearance and functional levels, and this may contribute to the inter-individual variations in the half-life of infused Factor VIII (FVIII) in hemophilia A (HA) patients. We investigated the role of ABO blood groups in regulating FVIII immunogenicity by evaluating their distribution in patients with severe (FVIII < 1 IU/dL) HA according to inhibitor development and other known relevant factors...
November 8, 2016: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/27813042/red-blood-cell-distribution-width-is-an-independent-predictor-of-outcome-in-patients-undergoing-thrombolysis-for-ischemic-stroke
#13
Gianni Turcato, Manuel Cappellari, Luca Follador, Alice Dilda, Antonio Bonora, Massimo Zannoni, Chiara Bovo, Giorgio Ricci, Paolo Bovi, Giuseppe Lippi
An appropriate and timely management, including early diagnosis and accurate prognostication, is the mainstay for managed care of patients with acute ischemic stroke. Since red blood cell distribution width (RDW) was found to be an independent predictor of clinical outcomes in patients with thrombotic disorders, we designed a retrospective observational study to investigate whether the RDW value may also retain predictive significance in stoke patients undergoing thrombolytic therapy. This retrospective study was based on all patients admitted to the Emergency Department (ED) of the University Hospital of Verona (Italy) with a diagnosis of ischemic stroke, who underwent systemic thrombolysis between January 2013 and June 2015...
November 3, 2016: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/27806384/diagnostic-challenges-in-acquired-von-willebrand-syndrome-a-complex-case-of-prostate-carcinoma-associated-acquired-von-willebrand-syndrome
#14
Paul-Emile Claus, Inge Van Haute, Eline Verhoye, Dries Deeren, Els Moreau
No abstract text is available yet for this article.
November 2, 2016: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/27829265/recent-advances-in-thrombosis-and-hemostasis-part-i
#15
Sam Schulman, Md Shahidul Islam
No abstract text is available yet for this article.
November 2016: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/27769084/pulmonary-embolism-response-teams
#16
Alison S Witkin, Savanah Harshbarger, Christopher Kabrhel
Pulmonary embolism is a common and often life-threatening event. Treatment options include anticoagulation alone, catheter-directed therapies, and surgical thromboembolectomy. While guidelines exist, there is often controversy over which treatment is most appropriate, particularly for intermediate-risk patients. The traditional care model, in which the primary team is responsible for consulting the appropriate specialists, may be inadequate and inefficient for emergent situations, as ensuring coordination and communication between various consulting services can be a time consuming and confusing process...
November 2016: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/27764883/epidemiology-of-familial-aggregation-of-venous-thromboembolism
#17
Bengt Zöller, Xinjun Li, Henrik Ohlsson, Jianguang Ji, Ashfaque A Memon, Peter J Svensson, Karolina Palmér, Björn Dahlbäck, Jan Sundquist, Kristina Sundquist
Familial aggregation (clustering) of venous thromboembolism (VTE) is the clustering of VTE within a family. Though several genes, such as antithrombin, protein C, protein S, factor V, and prothrombin are associated with the familial clustering of VTE, these loci only partially explain the familial aggregation of VTE. The epidemiology of the familial aggregation of VTE exhibits typical characteristics of complex traits. The family history of VTE in first-degree relatives is associated with a two to three times increased familial relative risk (FRR)...
November 2016: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/27764882/the-outpatient-treatment-of-venous-thromboembolism-operational-impact-and-the-role-of-novel-anticoagulants
#18
Benjamin White, Rachel Rosovsky, Blair Alden Parry, Christopher Kabrhel
Pulmonary embolism (PE) and venous thromboembolism (VTE) are common diagnoses in the emergency department (ED), with significant potential morbidity and mortality. As a result, historically nearly all patients with PE have been admitted to the hospital for observation and treatment. In recent years, the ability to rapidly and accurately risk stratify patients with VTE according to their risk of short-term clinical deterioration has supported outpatient treatment, and non-vitamin K antagonist oral anticoagulants (NOACs) have further facilitated this approach...
November 2016: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/27764881/update-on-the-treatment-of-venous-thromboembolism
#19
Sam Schulman
During the past 7 years, results from phase III trials comparing nonvitamin antagonist K oral anticoagulants (NOACs) with vitamin K antagonists (VKAs) or with placebo, including 34,900 patients, have been published. Recent guidelines have been updated and now suggest treatment with NOACs rather than with VKA. Other updates in the guidelines concern the initial thrombolytic treatment for selected patients with deep vein thrombosis or pulmonary embolism as well as the possibility of withholding anticoagulation for minimal venous thromboembolism...
November 2016: Seminars in Thrombosis and Hemostasis
https://www.readbyqxmd.com/read/27764880/extensive-computed-tomography-versus-limited-screening-for-detection-of-occult-cancer-in-unprovoked-venous-thromboembolism-a-multicenter-controlled-randomized-clinical-trial
#20
Paolo Prandoni, Enrico Bernardi, Fabio Dalla Valle, Adriana Visonà, Pietro F Tropeano, Carlo Bova, Eugenio Bucherini, Md Shahidul Islam, Andrea Piccioli
Patients with unprovoked venous thromboembolism (VTE) may harbor occult cancer. Whether an extensive diagnostic work-up for cancer has additional value over a more limited screening for detection of underlying malignancy in these patients is controversial. We performed a randomized multicenter trial to assess if in patients with unprovoked VTE, a computed tomography (CT)-based diagnostic strategy including thoracic, abdominal, and pelvic CT in combination with fecal occult blood test yields a higher cancer detection rate than a nonstandardized testing approach based on physicians' clinical judgment and patients' preferences...
November 2016: Seminars in Thrombosis and Hemostasis
journal
journal
25105
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"